Anhui FDA To Question Pharma Heads In Severe Quality, Safety Cases
This article was originally published in PharmAsia News
Anhui FDA recently introduced the Anhui Pharma Manufacturer Discussion System, which requires regulator talks with pharma heads in the event of severe quality and safety concerns to tackle problems at the source.
You may also be interested in...
The pharma giants are joining forces to help the UK reach its ambitious target of testing 100,000 people a day for coronavirus by the end of April.
Angelini is looking to take its recently-acquired ThermaCare brand to the next level by establishing a direct base in Germany to market the product and through a new distribution deal with Norway's Navamedic.
BD and BioMedomics have released a new rapid point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19.